Fresenius reported FY/2025 organic revenue growth of 7% and EBIT growth of 6%, and said EPS rose 16%. Net debt/EBITDA was 2.7x at FY/2025, compared with 3.8x in FY/2022. In Q4/2025, Fresenius posted revenue of EUR 5.9 billion (+9% organic), EBIT of EUR 713 million (+13%), and core net income of EUR 440 million (+16%), with an EBIT margin of 12.1%. Operating cash flow was EUR 1.3 billion and interest expense was EUR -77 million; the tax rate was 27.4%. Fresenius proposed a FY/2025 dividend of EUR 1.05 per share (37% payout ratio). By division, Fresenius Kabi reported Q4/2025 revenue of EUR 2.2 billion (+10% organic) and EBIT of EUR 360 million (+7%), with an EBIT margin of 15.8%; it highlighted 16% organic revenue growth in “Growth Vectors,” driven by Biopharma. Fresenius Helios reported Q4/2025 revenue of EUR 3.5 billion (+8% organic) with an EBIT margin of 11.7%; Helios Spain delivered 11% organic revenue growth and a 15.0% EBIT margin, while Helios Germany reported 6% organic revenue growth, 52% EBIT growth and a 9.4% EBIT margin. On products and pipeline, Fresenius Kabi highlighted TYENNE (tocilizumab) with 37% market share in EU4+UK and 17% in the U.S., and launches of OTULFI (ustekinumab) and CONEXXENCE/BOMYNTRA (denosumab), including more than 100 contracts signed for denosumab since launch and 47 million lives covered across pharmacy and medical benefit access. Fresenius also said FY/2025 new products delivered more than EUR 500 million in revenue at more than 20% EBIT margin. For FY/2026, Fresenius guided for 4%–7% organic revenue growth (FY/2025 base: EUR 22.6 billion) and 5%–10% core EPS growth (FY/2025 base: EUR 2.87).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fresenius SE & Co. KGaA published the original content used to generate this news brief on February 25, 2026, and is solely responsible for the information contained therein.